{
  "nctId": "NCT05537922",
  "briefTitle": "I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy",
  "officialTitle": "I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy",
  "protocolDocument": {
    "nctId": "NCT05537922",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2022-06-22",
    "uploadDate": "2022-09-05T14:14",
    "size": 1217801,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT05537922/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 2200,
    "enrollmentType": "ESTIMATED"
  },
  "timeline": {
    "startDate": "2022-10-01",
    "completionDate": "2027-10-01",
    "primaryCompletionDate": "2025-10-01",
    "firstSubmitDate": "2022-09-05",
    "firstPostDate": "2022-09-13"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Age \\>/= 18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2.\n* Histologically confirmed diagnosis of stage IIIB/C-IV Non-Small-Cell Lung Cancer\n* Received any line immunotherapy (maintenance therapy with Durvalumab is allowed) for retrospective cohort; clinical indication for frontline treatment with immunotherapy as first line treatment for prospective cohort.\n* Patients with CNS metastasis are allowed\n* Patients with driver genomic alterations are allowed (only for retrospective cohort)\n* Evidence of a personally signed and dated ICF indicating that the patient has been informed of and understands all pertinent aspects of the study before enrolment (only for prospective cohort)\n* Availability of at least one FFPE block for -omics data generation (only for prospective cohort)\n\nExclusion Criteria:\n\n* Patients without minimal treatment information data to be included in the retrospective cohort\n* Prior treatment for advanced disease (only for prospective cohort)\n* Unavailability or inability to comply with the requested study procedures, including compilation of QoL questionnaires",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Response Rate",
        "description": "Prediction of response to immune checkpoint inhibitors in NSCLC",
        "timeFrame": "8 weeks (i.e. first radiological evaluation)"
      }
    ],
    "secondary": [
      {
        "measure": "PFS",
        "description": "Progression Free Survival in NSCLC treated with immune checkpoint inhibitors",
        "timeFrame": "From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months"
      },
      {
        "measure": "OS",
        "description": "Overall Survival in NSCLC treated with immune checkpoint inhibitors",
        "timeFrame": "From date of enrollment until the date of death from any cause, assessed up to 120 months"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 2,
      "otherCount": 0,
      "totalCount": 3
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 39,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:47.905Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}